EICHORPublic-registry trials using AC-101 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
AC-101 appears in 1 registered trial Eichor's radar has found, sponsored by Accro Bioscience (Suzhou) Limited, the most recent registered as Phase 2, with a planned enrollment of 153. Registered timeline: 2026–2027. The registry holds 440 registered studies for Ulcerative Colitis (UC).
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of AC-101 Tablets in Patients With Ulcerative Colitis | Accro Bioscience (Suzhou) Limited | Ulcerative Colitis (UC) | PHASE2 | 0 |
| Status | Not Yet Recruiting · planned start 2026-08 |
| Primary completion | 2027-11 |
| Enrollment target | 153 participants |
| Design | Randomized · Parallel · Phase 2 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | not yet posted — the record updates as sites are announced |
All fields verbatim from the ClinicalTrials.gov record for NCT07755241.
| First registered study | July 2025 — NCT07083193 (Accro Bioscience (Suzhou) Limited) |
| Registered studies matching this name | 2 all-time · 1 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 440 registered studies for Ulcerative Colitis (UC). Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Ulcerative Colitis (UC) drugs
← Eichor home · All tracked trials · Ulcerative Colitis (UC) studies · Weekly briefs
